NRx Pharmaceuticals (NasdaqCM:NRXP) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsJonathan Javitt - Founder, Chairman and CEOMichael Abrams - CFOPatrick R. Trucchio - Managing Director of Equity ResearchConference Call ParticipantsEdward Moon - AnalystThomas Shrader - Managing Director and Senior Biotechnology Equity Research AnalystOperatorMorning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 Results Conference Call. At this time, all lines are in listen-only ...

NRx Pharmaceuticals (NasdaqCM:NRXP) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsJonathan Javitt - Founder, Chairman and CEOMichael Abrams - CFOPatrick R. Trucchio - Managing Director of Equity ResearchConference Call ParticipantsEdward Moon - AnalystThomas Shrader - Managing Director and Senior Biotechnology Equity Research AnalystOperatorMorning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 results conference call. At this time, all lines are in listen-only ...

NRx Pharmaceuticals (NasdaqCM:NRXP) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Speaker3Morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Tuesday, March 24, 2026. I would now like to turn the ...

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one ...

NRx Pharmaceuticals logo Key Points 2025 described as "extraordinarily pivotal": NRx said it is "in the FDA" with at least one drug it hopes could be approved this year and is operating revenue-generating clinics treating patients daily. Stockholders approved all four proposals, including the election of Chaim Hurvitz and Michael Taylor as Class I directors, an amendment to the 2021 Omnibus Incentive Plan, ratification of Weinberg & Company as auditor, and a non-binding say-on-pay vote. Management sa ...

NRx Pharmaceuticals, Inc. (NRXP) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +323.53%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.18, delivering a surprise of -63.64%.Over the last four quarte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Address of principal executi ...

PresentationAt this time, I would like to now introduce Jonathan Javitt, Chairman of the Board of Directors of NRx Pharmaceuticals, Inc.[Operator Instructions] The polls are now open, viewers can go to www.cstproxy.com/nrxpharma/2026, as shown in the chat box for all attendees.Hello, everyone, and welcome to NRx Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders. Before we get started, I would like to go over a few logistical items so you know how to participate in today's meeting.Jonathan JavittCo ...

Core Insights - New to The Street is a prominent financial media brand that broadcasts weekly on Bloomberg Television and Fox Business, reaching millions of households across the U.S., Latin America, and MENA regions [6] Group 1: Featured Companies - FreeCast (NASDAQ:CAST) is transforming digital media aggregation and streaming access for consumers worldwide [3] - KLED.ai is advancing AI-driven enterprise and data intelligence solutions [3] - Lantern Pharma (NASDAQ:LTRN) is a leader in AI-powered oncology drug development [3] - BlackBarn Restaurant is a premier culinary destination in New York City known for its farm-to-table excellence [3] - Virtuix (NASDAQ:VRTX) specializes in immersive virtual reality technology [4] - NRx Pharmaceuticals (NASDAQ:NRXP) focuses on advanced therapeutics for critical conditions [4] - PetVivo Holdings is involved in veterinary regenerative medicine [4] - DataVault AI (NASDAQ:DVLT) provides data monetization and tokenization infrastructure [4] - Roadzen (NASDAQ:RDZN) offers an AI-powered insurance and mobility platform [4] - Stardust Power (NASDAQ:SDST) is engaged in lithium and energy infrastructure solutions [4] - CISO Global (NASDAQ:CISO) is an enterprise cybersecurity leader [4] - The Sustainable Green Team (OTC:SGTM) focuses on climate and sustainable infrastructure solutions [4] Group 2: Media Reach and Impact - New to The Street has a combined platform reach exceeding 5.1 million subscribers, including 4.44 million on its YouTube channel and over 700,000 on the NewsOut Digital Network [4][5] - The platform utilizes various distribution channels, including LinkedIn, X, Instagram, and Facebook, along with iconic billboard placements in Times Square and NYC's Financial District [4] - New to The Street continues to outperform traditional financial media platforms in terms of reach, engagement, and measurable impact, establishing itself as a dominant force in next-generation financial media [5]

Core Insights - NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for depression, PTSD, and suicide prevention [1] Financial Performance - The company is expected to report a Q4 2025 loss per share of approximately -$0.09 and projected revenue of around $7.53 million [2] - NRXP has a negative trailing P/E ratio of around -1.07, indicating it is not currently profitable [3] - The price-to-sales (P/S) ratio is very high at approximately 135–138, and the enterprise value to sales ratio is reported around 258–264, highlighting elevated valuation relative to current revenue [3][4] Cash Flow and Liquidity - The enterprise value to operating cash flow ratio remains negative, indicating ongoing cash burn and difficulties in generating positive cash flow from operations [4] - The company has a deeply negative earnings yield and negative shareholders' equity, leading to a negative book value per share of around -$0.93 [5] - The current ratio is 0.29, suggesting potential liquidity concerns as current assets may not sufficiently cover short-term liabilities without additional financing or revenue growth [5]